The Business Case for Prevention and Early Detection

Your genetics program is a revenue center – and your CFO should know about it.

Health systems benefit in many ways from high-risk cancer screening and early detection programs. In this installment of CancerIQ’s new series, The Business Case, we focus on downstream revenue: examining how genetics programs can measure the financial impact of their clinical services in a fee-for-service model.

John Hansel, MBA, CancerIQ’s Senior Vice President of Commercial Strategy, explores how your team can transform your genetics program into a revenue center and build the business case to impact more patients.